(Q38065105)

28 August 2017

1 reference

title

Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia (English)

1 reference

28 August 2017

1 reference

1 reference

1 reference

1 reference

Thomas Haak

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

29 November 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

29

1 reference

28 August 2017

issue

12

1 reference

28 August 2017

page(s)

1005-1015

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-012-0066-0

28 August 2017

exact match

0 references

cites work

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Management of type 2 diabetes: new and future developments in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Important differences: Canadian Diabetes Association 2008 clinical practice guidelines and the consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Review of linagliptin for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Hyperglycemic crises in adult patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Short-term intensive insulin therapy in newly diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

No need for the needle (at first).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Pro's and con's of the early use of insulin in the management of type 2 diabetes: a clinical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Lessons in initiating insulin in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Potential roles of erythropoietin in the management of anaemia and other complications diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Induction of Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients by Transient Intensive Insulin Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-012-0066-0

10.1007/S12325-012-0066-0

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1050181149

0 references

1 reference